Skip to main content
SpringerLink
Log in

1139 Emea Adviseert Contra-Indicatie Bij Rimonabant (Acomplia®)

  • Published:
Zorg en Financiering

Samenvatting

Het Europese bureau voor geneesmiddelenbeoordeling (EMeA) adviseert Acomplia (rimonabant) niet voor te schrijven aan patiënten die antidepressiva gebruiken en aan patiënten met ernstige depressie.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. www.zorgenfinanciering.nl

       

Authors
  1.    
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

 ,  . 1139 Emea Adviseert Contra-Indicatie Bij Rimonabant (Acomplia®). ZOFI 6, 87 (2007). https://doi.org/10.1007/BF03094431

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03094431

Search

Navigation